

Hereford Funds

DSM US Large Cap Growth Fund

August 2008

August 2008 Investment Review

The Hereford/DSM Large Cap Fund declined (0.2%) for the month of August compared to a 1.1% appreciation for the Russell 1000 Growth index and a 1.5% appreciation for the S&P500. Consistent with last month, the majority of the fund remains invested in the health care, technology, business services, and energy services sectors. The weighted average P/E of the portfolio is 18.2x, which we feel is attractive relative to our estimated earnings growth of 20%.

For the past number of months we have focused much attention on the movement of commodity prices, oil in particular. With respect to oil, it appears that the sell off is largely a response to expectations for a global economic slowdown. Unemployment in the U.S. reached 6.1% recently, a level not seen since 2004, and a significant jump from the 4.5% level we had seen during 2007. China's Shenzen Index is down approximately 60% year-to-date, foreshadowing a likely slowdown in economic activity. With the U.S. representing 25% of global oil demand and China representing 80% of incremental demand, it is not surprising that a coincident slowing in these two economies would place significant downward pressure on the price of oil. It remains unclear as to whether the actual supply/demand picture will change significantly enough to keep a lid on future advances in oil prices. For the near term at least, the drop in oil and other commodity prices is a clear positive for the stock market.

We made several changes to the portfolio during the month of August. We initiated new positions in C.R. Bard (BCR), Mastercard (MA), and Nestle (NSRGY). BCR is a manufacturer of medical equipment that we have followed for some time and purchased opportunistically following a period of weak performance. We had owned BCR stock earlier in the year and sold it at higher valuation levels. MA is a provider of services and support for electronic payment solutions including credit and debit cards. The stock has sold off significantly due in part to fears of an overall economic slowdown. We believe it now trades at a very attractive valuation given its strong franchise and lack of credit risk. Nestle is a global manufacturer of food products that should generate low double-digit earnings growth.

Also during the month, we sold Varian (VAR) for valuation reasons as the stock has moved up over 20% since the middle of July. We trimmed Celgene (CELG) due to near term concern over reports of a potentially serious side effect being observed in patients taking Revlimid. We have since had a chance to review these reports more carefully and discuss them with management. Our initial fears have been allayed to a large degree and we remain very bullish on the prospects for the company. We also trimmed Hologic (HOLX) following their quarterly earnings report which made us incrementally less confident in their near term prospects.


Key information

NAV A Shares (29/08/08): \$93.10 Total Fund Size: \$38.2 mil Strategy Assets: \$1,582.5 mil (a) Fund Launch Date: 29-Nov-07

Monthly Performance (%)

| | Jan | i en | IVIAI | Aþi | iviay | Juli | Jui | Aug | Seb | OCL | INOV | Dec | שוו |
|-----------------------------|-------|-------|-------|-----|-------|-------|-------|-------|-----|-----|------|-----|--------|
| Hereford Funds NAV | (7.7) | (3.1) | 8.0 | 6.5 | 2.9 | (4.0) | (1.5) | (0.2) | | | | | (6.7) |
| Russell 1000 ^(c) | (7.8) | (2.0) | (0.6) | 5.3 | 3.7 | (7.2) | (1.9) | 1.1 | | | | | (9.8) |
| S&P 500 ^(c) | (6.0) | (3.3) | (0.4) | 4.9 | 1.3 | (8.4) | (8.0) | 1.5 | | | | | (11.4) |
| | | | | | | | | | | | | | |

| Period Performance (%) | | | | | | | Since Incep | Since Inception 01/01/02 | | |
|---|--------|------|------|------|------|------|-------------|--------------------------|------------|--|
| | YTD | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | Cumulative | Annualised | |
| DSM LCG/Hereford LCG Returns ^(b) | (6.7) | 18.7 | 9.8 | 11.4 | 9.4 | 25.2 | (17.7) | 52.5 | 6.5 | |
| Russell 1000 ^(c) | (9.8) | 11.8 | 9.1 | 5.3 | 6.3 | 29.7 | (27.9) | 15.2 | 2.1 | |
| S&P 500 ^(c) | (11.4) | 5.5 | 15.8 | 4.9 | 10.9 | 28.7 | (22.1) | 26.2 | 3.6 | |





| Top Ten Holdings | % NAV | Sectoral Breakdown | % of Assets |
|------------------|-------|------------------------|-------------|
| Celgene Corp | 8.4% | Health Care | 34.3% |
| Schlumberger Ltd | 7.5% | Information Technology | 21.0% |
| Genzyme Corp | 5.8% | Energy | 14.8% |
| Google Inc-Cl A | 4.6% | Services | 7.4% |
| Monsanto Co | 4.5% | Industrials | 6.3% |
| ABB | 4.2% | Financials | 5.6% |
| Schering Plough | 4.0% | Consumer Staples | 4.9% |
| Stryker | 3.9% | Materials | 4.5% |
| Adobe Systems | 3.6% | | |
| SEI Investments | 3.5% | | |

Investment Objective

The investment objective of the sub fund is to provide capital appreciation principally through investments in US-based growing corporations with market capitalizations generally above 2 billion dollars. These companies are chosen for their growth prospects, attractive returns, solid business fundamentals and intelligent management. The sub fund may, on an ancillary basis, invest in US-based companies with lower market capitalizations as well as in non-US based companies. The Compartment may invest in American Depository Receipts and American Depository Shares. The reference benchmark for this strategy is the Russell 1000 Growth Index.

| Fund Codes (Share Class A) | | Since Inception Risk Profile | DSM US LCG | DSM LC | R1000 Growth |
|----------------------------|--------------|---------------------------------|------------|--------|--------------|
| Bloomberg | DSMUSLA LX | Volatility | n/a | 11.29 | 12.91 |
| ISIN | LU0327604228 | Sharpe Ratio | n/a | 0.25 | -0.12 |
| Reuters | LP65102015 | Information Ratio | n/a | 0.45 | |
| Sedol | B28TLX2 | Tracking Error | n/a | 8.24 | |
| Valoren | 3504726 | Beta | n/a | 0.68 | |
| WKN | A0M58T | Alpha | n/a | 4.12 | |

Fund Details

Dealing day Daily

None - income accumulated within the fund Dividends

Investment Manager DSM Capital Partners LLC, 320 East Main Street, Mount Kisco, NY 10549, USA Promoter VP Bank (Luxembourg) S.A., 26 Avenue de la Liberté, L-1930 Luxembourg

Authorized Corporate Director VPB Finance S.A., 26 Avenue de la Liberté, L-1930 Luxembourg

Custodian VP Bank (Luxembourg) S.A., 26 Avenue de la Liberté, L-1930 Luxembourg Elvinger, Hoss & Prussen, 2 Place Winston Churchill, L-1340 Luxembourg Legal Advisers

Deloitte,560 Rue de Neudorf, L-2220 Luxembourg Auditor

Annual Management Charge

Share Class A & U^(e) 1.25%

Share Class B 0.25% + 20% performance fee on outperformance vs US T-Bill with HWM Share Class C(d) 1% + 20% performance fee on outperformance vs US T-Bill with HWM Share Class D

Minimum Investment

\$100,000 initial / \$10,000 subsequent Share Class A&B Share Class C&D \$10,000 initial / \$1,000 subsequent

Order Transmission / Information Original Applications To:

VPB Finance S.A. attn. Fund Operations / TA-HFF P.O. Box 923

L-2019 Luxembourg

or, for transmissions via courier service, 26, avenue de la Liberté, L-1930 Luxembourg

Subsequent Applications Only Via Facsimile:

VPB Finance S.A.

attn. Fund Operations / TA-HFF (+352) 404 770 283 Fax: (+352) 404 770 260 Tel:

e-mail: luxfunds.info@vpbank.com

- This refers to the total assets invested in the reference strategy managed by the Investment Manager
 Data and graph depict DSM Composite through November 2007 and Hereford Funds DSM US Large Cap Growth Fund Class A thereafter.
 Historical gross performance of DSM Large Cap Composite returns (the Reference Strategy) minus modeled fee and expense typical of
 Hereford Funds DSM US Large Cap Growth Fund Class A (1.25% fee + 0.25% expense). Fund follows same strategy. Performance presentation incomplete without accompanying footnotes as shown at dsmcapital.com
- Total return including dividends.
- Share Class C is German tax registered from 4/1/08.
- (e) Share Class U: UK Distributor Status to the year ending 30th September 2008 Pending

This document is for information purposes use only. It is neither an advice nor a recommendation to enter into any investment. Investment suitability must be determined for each investor, and this fund may not be suitable for all investors. This information does not provide any accounting, legal, regulatory or tax advice. Investors should consult professional advisers to evaluate this information. An investment should be made only on the basic of the Prospectus, the annual and any subsequent semi-annual-reports of HEREFORD FUNDS (the "Fund"), a société d'investissement à capital variable, established in Luxembourg and registered under Part I of Luxembourg law of 20 December, approved by the Commission de Surveillance du Secteur Financier (CSSF). These can be obtained from [the Fund, 26, avenue de la Liberté, L-1930 Luxembourg or from VPB Finance S.A., 26, avenue dela Liberté, L-1930 Luxembourg and any distributor or intermediary appointed by the Fund]. No warranty is given in whole or in part, regarding performance of the Fund. There is no guarantee that its investment objectives will be achieved. Investors should be aware that the value of investments can fall as well as rise and that they may not recover the full amount invested. Past performance is no guide to future performance. The information provided in this document may be subject to change without any warning or prior notice and should be read in conjunction with the most recent publication of the Prospectus of the Fund. While great care is taken to ensure that this information is accurate, no responsibility can be accepted for any errors, mistakes or omission or for future returns. This document is intended for the use of the addressed only and may not be reproduced, redistributed, passed on or published, in whole or in part, for any purpose, without the prior written consen of HEREFORD FUNDS. Neither the CSSF nor any other regulator has approved this document. Full details of the investment policy and objectives are stated in the Prospectus.